Financial results - ELITE PHARMA S.R.L.

Financial Summary - Elite Pharma S.r.l.
Unique identification code: 11166158
Registration number: J04/1007/1998
Nace: 7022
Sales - Ron
11.447
Net Profit - Ron
1.367
Employee
The most important financial indicators for the company Elite Pharma S.r.l. - Unique Identification Number 11166158: sales in 2023 was 11.447 euro, registering a net profit of 1.367 euro and having an average number of employees. Firma isi desfasoara activitatea in domeniul Activitati de consultanta pentru afaceri si management having the NACE code 7022.

Sales, Profit, Employees, Debts, Capitals, Financial Results - Elite Pharma S.r.l.

2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Sales - EUR 12.559 6.097 2.227 2.207 5.130 9.096 8.911 9.248 10.846 11.447
Total Income - EUR 12.559 6.097 2.227 2.207 5.144 9.096 8.911 11.224 11.819 14.101
Total Expenses - EUR 11.304 17.308 12.010 7.796 4.750 6.186 4.276 8.866 9.632 12.437
Gross Profit/Loss - EUR 1.255 -11.212 -9.783 -5.589 394 2.910 4.635 2.358 2.188 1.664
Net Profit/Loss - EUR 878 -11.394 -9.850 -5.656 239 2.637 4.367 2.114 1.885 1.367
Employees 0 0 0 0 0 0 0 0 0 0
The table presents the most important indicators of the company from the Profit and Loss Account for the last 10 years of activity. The data show the company's evolution during this period, highlighting any increases or potential decreases recorded. In the last year of activity, the sales increased by 5.9%, from 10.846 euro in the year 2022, to 11.447 euro in 2023. The Net Profit decreased by -512 euro, from 1.885 euro in 2022, to 1.367 in the last year.

Check the financial reports for the company - Elite Pharma S.r.l.

Rating financiar

Financial Rating -
Elite Pharma S.r.l.

See the company's note based on the submitted financial data, relative to the industry of which it is a part.

Check Financial Rating
Limite de plata

Payment Limits -
Elite Pharma S.r.l.

See the company's payment capacity for situations in which you conclude contracts with payment terms.

Check Payment Limits
Probabilitate de insolventa

Prob. of insolvency -
Elite Pharma S.r.l.

It determines the risk of insolvency based on the submitted accounting balance.

Check Insolvency Probability
Rapoarte financiare

Financial Reports -
Elite Pharma S.r.l.

Check all the financial reports of the company and know the risks in collaboration with it.

Check Financial Reports
Financial Analysis Reports provide a clear and comprehensive view of a company's financial activity. In addition to presenting financial data, the reports analyze this data so that any user can understand whether the results are positive or less favorable. The Financial Rating provides an analysis based on the most important financial ratios, including liquidity, solvency, and profitability. Payment Limits represent the maximum amounts for which a company can offer goods or services on credit to its clients. The Probability of Insolvency presents the theoretical probability that a company may not be able to meet its financial obligations towards its creditors, i.e., suppliers and financial institutions.

Debts, Equity, Inventories, Receivables, Accounts, Assets - Elite Pharma S.r.l. - CUI 11166158

2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
Fixed Assets 108.218 110.868 108.038 102.094 99.180 93.161 80.681 78.920 86.046 84.830
Current Assets 20.348 16.859 4.965 4.361 5.804 3.159 6.171 5.826 3.093 5.568
Inventories 0 181 0 0 968 0 0 0 0 0
Receivables 1.008 3.988 4.168 3.775 3.137 1.767 926 91 312 195
Cash 19.340 12.690 797 586 1.699 1.391 5.245 5.736 2.781 5.373
Shareholders Funds 127.326 116.994 105.951 95.482 93.969 91.422 84.234 84.480 84.935 86.045
Social Capital 67 67 67 66 64 63 62 61 61 61
Debts 1.240 10.732 7.052 10.972 11.015 4.899 2.618 266 4.203 4.353
Income in Advance 0 0 0 0 0 0 0 0 0 0
Exchange rate - RON 4.9465 4.9315 4.9468 4.8371 4.7454 4.6535 4.5681 4.4908 4.445 4.4821
Main CAEN "7022 - 7022"
CAEN Financial Year 7022
The table presents the company's Balance Sheet structure for the last 10 years. Current Assets recorded a value of 5.568 euro in 2023 which includes Inventories of 0 euro, Receivables of 195 euro and cash availability of 5.373 euro.
The company's Equity was valued at 86.045 euro, while total Liabilities amounted to 4.353 euro. Equity increased by 1.367 euro, from 84.935 euro in 2022, to 86.045 in 2023.

Activate the Financial Reports subscription with unlimited access and check the evolution and current financial situation of any company.

Subscriptions Financial Reports

You can check the financial situation of the companies in relation to the industry of which it is a part, credit limits and the risk of insolvency and suspension of accounts.

Subscription cost is per user. You can pay simultaneously up to 10 users.
RisCo Subscriptions offer the greatest flexibility in choosing the best services according to the needs of each user. These are structured into categories based on the type of service desired, as well as on different service contract periods: monthly, semi-annually, and annually. Check out the subscription offer for the best choices!

Reviews - Elite Pharma S.r.l.

Comments - Elite Pharma S.r.l.

Similar services useful for checking companies and business development.

Contacts Firms

Get the contact details for any company and get in touch with it.

Sectoral Studies

Knows the market and develops its own development strategies according to sectorial data.

Company Lists

Create lists of companies for your sales activity according to your own criteria.

Import - Export

Find importers and exporters according to the type of activity and the countries in which they carry it out.

Similar services represent services associated with companies that allow for a better analysis of clients and suppliers. Company Contacts help you get in touch with the desired companies. Sector Studies provide an overview of an industry, the most important competitors, and the geographical distribution of companies. Company Lists allow you to attract new clients, while Import-Export services give you access to companies engaged in such activities.